A Review of Long-Acting Reversible Contraception Methods and Barriers to Their Use

Melyssa Baron; Beth Potter, MD; Sarina Schrager, MD, MS

ABSTRACT
Unplanned pregnancies are a serious health concern in Wisconsin. Increasing access to contraception is a proven method to reduce unplanned pregnancies while giving patients greater agency. Long-acting reversible contraception (LARC) methods, such as subdermal implants and intrauterine devices (IUD), are among the most effective contraception methods available and have high patient satisfaction. However, relatively few Wisconsin patients use these methods. Lack of provider skill in inserting and counseling about LARCs, inability to perform same-day LARC insertion, and absent hospital protocols for immediate postpartum insertion represent barriers to LARC access. Centralized efforts are required to remove these barriers so that all patients in Wisconsin can access highly effective contraception.

BACKGROUND
In 2011, 37% of all Wisconsin pregnancies were unplanned. Patients with unplanned pregnancies are more likely to delay prenatal care, experience maternal depression, and face violence during pregnancy. These pregnancies are more likely to end in abortion, while infants born are more likely to face health problems. An unplanned pregnancy can reduce parents’ educational attainment and earning potential. Unplanned pregnancies also carry financial implications for families, hospital systems, and state entitlement programs.

Increasing access to all family planning methods is an effective and cost-efficient strategy to decrease unplanned pregnancies in Wisconsin. Long-acting reversible contraception (LARC) methods are among the most effective contraception methods. They prevent pregnancy for 3 to 10 years, independent of user action. In studies where women are provided no-cost contraception, 20% to 42% of women choose LARCs. (Note that no studies have thus far investigated LARC use among transgender men or nonbinary patients.) Despite the data, only 4.4% to 5.7% of Wisconsin women enrolled in Medicaid currently use a LARC. This low uptake is linked to several barriers preventing patients from receiving their contraception of choice.

What Are LARCs?
LARC is a term used to describe contraceptive methods that are reversible but do not require any action by the user to be effective. There are 2 types of LARC available in the United States: etonogestrel single rod subdermal implants and intrauterine devices (IUD). There are 5 different IUDs available in the United States, 4 with progestin and 1 copper IUD. (See Table) Both the implant and the IUDs require a visit with a trained clinician. Clinicians are trained to insert IUDs during residency training but have to complete an FDA-approved, industry-sponsored program in order to be certified to insert the contraceptive implant. Nurse practitioners and physician assistants also may be trained by their colleagues to insert LARC.

How Do LARCs Work?
The etonogestrel contraceptive implant (marketed as Nexplanon) releases a low level of progestin during the 3 years it is in place. This low level of progestin leads to thickened cervical mucus and suppression of ovulation. The typical failure rate is 0.05%, which makes it one of the most effective contraceptive methods available. The implant is inserted in the upper, inner aspect of the nondominant arm with a procedure that takes less than 5 minutes. After insertion, the main side effect is changes in menstrual bleeding patterns. Patients may experience a variety of different bleeding patterns ranging from frequent spotting to amenorrhea. This low-dose progestin method does not confer many of the traditional side effects seen with other progestin-only methods such as weight gain and headache.
There are 5 different IUDs available in the United States (Table). The Copper T-380 IUD is a nonhormonal method of contraception. The copper IUD’s main mechanism of action is to prevent fertilization by impacting sperm migration and viability. It does not interfere with existing pregnancies. It has a failure rate of 0.08%, which is comparable to the annual failure rate of a tubal ligation. The most common side effect of the copper IUD is menstrual bleeding and pelvic pain. There are no hormonal side effects. It can also be used as emergency contraception (preventing pregnancy) if inserted up to 5 days after unprotected intercourse.

There are 4 different hormonal IUDs, each with levonorgestrel (LNG). These IUDs prevent pregnancy by causing thickened cervical mucus (a progestin effect). A secondary effect of the LNG-IUDs is that the progestin induces endometrial thinning and atrophy, which then causes decreased menstrual bleeding in many patients, usually after a period of irregular bleeding. The LNG-IUDs do not interrupt an existing pregnancy.

New guidelines for IUD insertion provide broader recommendations. IUDs are appropriate for teenagers, patients who have not had children, and patients who have had a pelvic infection in the past. Similar day IUD insertions are acceptable if a reasonable exclusion of pregnancy is performed.

## DISCUSSION

### Clinical Use of LARC

Both IUDs and the contraceptive implant should be routinely offered as contraceptive options to adolescent and nulliparous women. There is no evidence showing an increased risk of complications when using IUDs in this population. No studies have demonstrated an increased risk of pelvic inflammatory disease or infertility in women using an IUD. Women who are at high risk for sexually transmitted infections can be tested for infection at the time of placement of the IUD and treated if the results are positive. As long as pregnancy can be reasonably excluded, an IUD or implant can be placed at any time during the menstrual cycle. Women should be counseled to use backup contraception for the first 7 days after placement of implant or LNG-IUD. A copper IUD is effective immediately and no backup contraception is required.

### Barriers

#### Provider Education

Provider knowledge gaps about LARCs directly affect provision. Specialty matters, as 88% of providers working in obstetrics and gynecology nationwide report providing LARCs, compared with only 24% of those working in internal medicine or pediatrics. Furthermore, 44.2% of family medicine practices report safety misperceptions surrounding LARCs, compared to only 14.7% of gynecology and obstetrics providers. Providers who receive continuing education about LARCs have fewer safety misperceptions and are more likely to include LARCs in their practices.

Some providers may believe that there are limitations in appropriateness of LARC usage. However, most expert panels agree that LARCs are suitable for nulliparous patients, teenagers, and patients with a history of ectopic pregnancy, sexually transmitted infections, abortion, depression, or obesity.

#### Same-Day Insertion

Attending a health appointment requires patients to schedule an additional appointment, requiring their patients to schedule an additional appointment. According to “Quick Start” insertion guidelines, there are many instances where a pregnancy test is not necessary, such as when a patient’s last menstrual period was less than 7 days ago. In addition, a progestin IUD or implant can be quick-started if a patient has not had unprotected sex since their last menstrual period.

#### Stocking LARC devices

There are 5 different IUDs available in the United States. These IUDs prevent pregnancy by causing thickened cervical mucus (a progestin effect). A secondary effect of the LNG-IUDs is that the progestin induces endometrial thinning and atrophy, which then causes decreased menstrual bleeding in many patients, usually after a period of irregular bleeding. The LNG-IUDs do not interrupt an existing pregnancy.

New guidelines for IUD insertion provide broader recommendations. IUDs are appropriate for teenagers, patients who have not had children, and patients who have had a pelvic infection in the past. Similar day IUD insertions are acceptable if a reasonable exclusion of pregnancy is performed.

#### DISCUSSION

### Clinical Use of LARC

Both IUDs and the contraceptive implant should be routinely offered as contraceptive options to adolescent and nulliparous women. There is no evidence showing an increased risk of complications when using IUDs in this population. No studies have demonstrated an increased risk of pelvic inflammatory disease or infertility in women using an IUD. Women who are at high risk for sexually transmitted infections can be tested for infection at the time of placement of the IUD and treated if the results are positive. As long as pregnancy can be reasonably excluded, an IUD or implant can be placed at any time during the menstrual cycle. Women should be counseled to use backup contraception for the first 7 days after placement of implant or LNG-IUD. A copper IUD is effective immediately and no backup contraception is required.

### Barriers

#### Provider Education

Provider knowledge gaps about LARCs directly affect provision. Specialty matters, as 88% of providers working in obstetrics and gynecology nationwide report providing LARCs, compared with only 24% of those working in internal medicine or pediatrics. Furthermore, 44.2% of family medicine practices report safety misperceptions surrounding LARCs, compared to only 14.7% of gynecology and obstetrics providers. Providers who receive continuing education about LARCs have fewer safety misperceptions and are more likely to include LARCs in their practices.

Some providers may believe that there are limitations in appropriateness of LARC usage. However, most expert panels agree that LARCs are suitable for nulliparous patients, teenagers, and patients with a history of ectopic pregnancy, sexually transmitted infections, abortion, depression, or obesity.

#### Same-Day Insertion

Attending a health appointment requires patients to schedule an additional appointment, requiring their patients to schedule an additional appointment. According to “Quick Start” insertion guidelines, there are many instances where a pregnancy test is not necessary, such as when a patient’s last menstrual period was less than 7 days ago. In addition, a progestin IUD or implant can be quick-started if a patient has not had unprotected sex since their last menstrual period.

#### Stocking LARC devices

There are 5 different IUDs available in the United States. These IUDs prevent pregnancy by causing thickened cervical mucus (a progestin effect). A secondary effect of the LNG-IUDs is that the progestin induces endometrial thinning and atrophy, which then causes decreased menstrual bleeding in many patients, usually after a period of irregular bleeding. The LNG-IUDs do not interrupt an existing pregnancy.
Wisconsin, allowing hospitals to bill Medicaid separately for the procedure and receive reimbursement for the costly devices. Despite these changes, obstacles to IPP LARC insertion remain. For an IUD to be inserted immediately after placental delivery, the device must be readily available where the patient is giving birth. However, many Wisconsin hospitals have yet to adapt their stocking procedures, order sets, and pharmacy formularies to allow for IPP insertion. Lack of provider training in performing IUD insertion postpartum is an additional barrier nationwide. An underutilized insurance option that Wisconsin offers is the Family Planning Only Services Program. This program provides low-income patients who are at least 14 years old with no cost family planning-related services (such as LARC insertion). These services and their notices are confidential, minors can apply for them on their own, and patients can access them even if they already have health insurance.

**Ideological Concerns**

Remembering past reproductive injustices is the first step to avoiding them in the future. Providers must know about the historical legacy of sterilization and forced contraceptive use against patients living in poverty, communities of color, and those with disabilities or mental illnesses. Researchers and advocates encourage thoughtfulness when promoting LARC use. LARC promotion may lead to coercion and targeting of certain patients if a social justice framework is not in place. Some people may have personal reservations towards LARC use. The 2016 “Future of the Family Commission” of the Wisconsin Department of Children and Families acknowledges that LARC use may “carry moral considerations that are unacceptable to segments of the population.” While LARCs do not interfere with an implanted embryo, some patients and providers may oppose their use due to religious or personal beliefs.

**Special Issues in Rural Patients**—Patients living in rural Wisconsin may have different challenges than patients living in urban areas. Some research suggests that women of reproductive age who live in rural areas have less access to contraceptive care. This access is likely related to shortages of women’s health providers in rural areas as well as clinic-based barriers. One survey of 558 family planning clinics in 16 Midwestern and Great Plains states found that clinics in rural areas had less access (shorter hours, no evening or weekend hours), fewer providers trained in IUDs, and less administration of hormonal contraception.

**Potential Benefits**

Removing barriers to LARC use gives patients and providers increased freedom when making decisions about family planning. In fact, when clinicians receive training in LARC insertion, billing policies, and counseling, patients report greater autonomy in choosing contraception. Women also report high satisfaction with LARCs in comparison to short-acting methods.

Programs in St. Louis and Colorado show that when barriers to LARC provision are removed, the unplanned pregnancy rate falls. The Colorado Family Planning Initiative began with a private donor’s investment in the state health department’s family planning program. Health providers received training in LARCs, family planning clinics received financial support, and low-income patients were able to receive their choice of contraception for little to no cost. Since the initiative began, births to women without a high school education fell 38%.

In St. Louis, the Contraceptive CHOICE project enrolled over 10,000 women to participate in a study where they would receive the contraception method of their choice. When counseled, over 75% of women chose a LARC method. LARC-using patients in St. Louis were 20 times less likely to get pregnant than those using short-acting methods.

Finally, increasing LARC access is cost-effective for patients, hospital systems, and entitlement programs. Once used for 2.1 years, LARCs are cost-saving for patients in comparison to short-acting methods. Models have shown that providing LARCs IPP is cost-saving for health care systems, saving $1,263 per patient in one estimate. The Colorado Family Planning Initiative avoided millions of dollars in costs to state entitlement programs such as Medicaid, Temporary Assistance for Needy Families, Supplemental Nutrition Assistance Program, and the Special Supplemental Nutrition Program for Women, Infants, and Children between 2010 and 2014.

**Current Efforts in Wisconsin and Beyond**

A handful of programs in Wisconsin increase patient access to LARCs. The Ryan Residency Training Program at Meriter Hospital in Madison provides free IPP LARCs to low-income women. The Collaborative Improvement and Innovative Network (CoIIN) to Reduce Infant Mortality has partners throughout Wisconsin working to improve the reproductive health content of postpartum visits and adolescent well checks. Wisconsin Contraceptive Access Network (CAN) is a fledgling initiative seeking to eliminate barriers to contraception via health care quality improvement, stakeholder engagement, and policy advocacy. These efforts are important, but they are not sufficient to eliminate barriers to LARC access in Wisconsin. Other states have seen success with more centralized programs, such as the Colorado Family Planning Initiative described above. One new example of such a program is Delaware, where the state has reallocated funding from its public health budget (alongside significant private funding) to partner with a nonprofit called Upstream USA. The program will train health care providers and billing staff so that all patients in major health care centers will be asked about their pregnancy plans and provided no-to
low-cost birth control if desired. If the initiative leads to a decrease in Medicaid spending and unplanned pregnancy rates, it may prove viable for application in other states such as Wisconsin.

There are also nationwide efforts to improve LARC access, such as the ASTHO Increasing Access to Contraception Learning Community. This initiative teaches strategies and best practices so states can implement policies and programs that increase access to all contraceptive methods. Twenty-seven states, including Iowa and Illinois, are partnered with ASTHO; Wisconsin currently is not one of them.

CONCLUSION
Improving access to LARCs is a cost-effective way to increase patient satisfaction and agency while reducing unplanned pregnancies. With the new low-cost IUD recently on the market (brand name Lilletta), clinics may be able to keep more IUDs in stock in the future, making same-day insertion more feasible. Increasing provider education so that providers know which patients can be provided with LARCs, how to insert LARCs, and when contraception can be given via “Quick Start” will decrease the need for patients to schedule additional appointments. Adapting stockin procedures, order sets, and pharmacy formularies to match current Medicaid policies surrounding IPP LARC insurance will allow more patients to receive LARCs immediately postpartum. Improving health care staff awareness of the Family Planning Only Services Program can increase the program’s utilization so that more Wisconsin patients have access to insurance providing no-cost LARCs. Lastly, health care providers can advocate for Wisconsin’s participation in more centralized efforts to improve LARC access, looking to programs such as the Colorado Family Planning Initiative, Delaware CAN, and the ASTHO Increasing Access to Contraception Learning Community as examples. Through knowledge, awareness, and advocacy, more Wisconsin patients will be able to access their contraception of choice.

Acknowledgments: Doctor Schrager serves as WMJ associate editor but was not involved in the review or acceptance of this manuscript for publication.

Funding/Support: None declared.

Financial Disclosures: None declared.

Planners/Reviewers: The planners and reviewers for this journal CME activity have no relevant financial relationships to disclose.

REFERENCES
The mission of *WMJ* is to provide a vehicle for professional communication and continuing education for Midwest physicians and other health professionals.

*WMJ* (ISSN 1098-1861) is published by the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in the Midwest. The managing editor is responsible for overseeing the production, business operation and contents of the *WMJ*. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socioeconomic, or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither *WMJ* nor the Wisconsin Medical Society take responsibility. *WMJ* is indexed in Index Medicus, Hospital Literature Index, and Cambridge Scientific Abstracts.

For reprints of this article, contact the *WMJ* at 866.442.3800 or e-mail wmj@wismed.org.

© 2018 Wisconsin Medical Society